Advertisement
Advertisement
U.S. markets close in 3 hours 10 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cerus Corporation (CERS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.8925+0.1425 (+3.80%)
As of 12:50PM EDT. Market open.
Advertisement

Cerus Corporation

1220 Concord Avenue
Suite 600
Concord, CA 94520
United States
925 288 6000
https://www.cerus.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees631

Key Executives

NameTitlePayExercisedYear Born
Mr. William M. GreenmanPres, CEO & Director1.25M2.22M1967
Dr. Laurence M. CorashCo-Founder & Chief Scientific Officer697.77k191.79k1944
Mr. Kevin D. GreenVP of Fin. & CFO698.15k384.75k1972
Mr. Vivek K. JayaramanChief Operating Officer845.3kN/A1975
Dr. Richard J. BenjaminChief Medical Officer718.64k533.87k1960
Ms. Lori L. RollVP of Admin. & Corp. Sec.N/AN/AN/A
Mr. Matthew M. NotarianniSr. Director of Investor RelationsN/AN/AN/A
Ms. Chrystal N. MenardChief Legal Officer & Gen. CounselN/AN/A1971
Lainie CortenVP of Global MarketingN/AN/AN/A
Ms. Carol M. MooreSr. VP of Regulatory Affairs, Quality & ClinicalN/AN/A1950
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Corporate Governance

Cerus Corporation’s ISS Governance QualityScore as of October 1, 2022 is 4. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement